Best Clean Energy Stocks To Own Right Now

Best Clean Energy Stocks To Own Right Now: Nektar Therapeutics(NKTR)

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The company?s product pipeline consists of drug candidates across various therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. Its research and development activities involve small molecule drugs, peptides, and other potential biologic drug candidates. The company?s proprietary drug candidates in clinical development comprise NKTR-118, a peripheral opioid antagonist, which has completed Phase II clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase II clinical trail to treat gram-negative pneumonias; NKTR-102, a topoisomerase I inhibitor-polymer conjugate, which is in Phase II clinical trail for multiple cancer indications, including breast, ovarian, and colorectal; and NKTR-105 that is in Phase I clinica l trail to treat solid tumors. Its preclinical products consists of NKTR-119 (Opioid/NKTR-118 combinations) for the treatment of pain; NKTR-181 (abuse deterrent, tamper-resistant opioid) to treat pain; NKTR-194 (non-scheduled opioid) for the treatment of mild to moderate pain; NKTR-171 (tricyclic antidepressant) to treat neuropathic pain; and NKTR-140 (protease inhibitor candidate) to treat HIV. The company has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. In addition, Nektar Therapeutics has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, ! Baxter, Roche, Merck, Pfizer, and UCB Pharma. The company was founded in 1990 and is headquartered in San Fran c isco, California.

Advisors' Opinion:

• [By John McCamant]

  Nektar Therapeutics (NKTR) is expected to get FDA approval this year for its lead drug naloxegol, a once-a-day pill for opioid-induced constipation (OIC). The drug is licensed to AstraZeneca. NKTR will receive up to $245 million in milestone payments, plus royalties.

• [By Jay Silverman]

  Jay Silverman: Oh, by the way, if you wanted me to throw a few of those names that might be considered, Novavax would be one of them, and Nektar (NKTR), and the Medicines Company (MDCO) and Pharmacyclics, which has been a great stock, but has come under pressure of late.

• [By Sean Williams]

  This is particularly intriguing now both to Allergan, which purchased MAP Pharmaceuticals earlier this year for $958 million, and to Nektar Therapeutics (NASDAQ: NKTR  ) , which would gain royalties from the sale of Levadex due to its intellectual property contribution to the making of the drug.

• [By Sean Williams]

  Levadex's approval or rejection could also mean a good or bad day for Nektar Therapeutics (NASDAQ: NKTR  ) , which looks to gain from royalty rights based on its contributions to Levadex's development. While impossible to predict, I'm going to go out on a limb and project an approval for Allergan.

source from Top Stocks Blog:http://www.topstocksblog.com/best-clean-energy-stocks-to-own-right-now.html